RECOVAC Repeated Vaccination Study

Optimal Repeated Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium

Radboud University Medical Center, Erasmus Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), ZonMw: The Netherlands Organisation for Health Research and Development

Rationale: The humoral and cellular immune response after two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate mofetil (MMF) / mycophenolic acid (MPA). A repeated dose strategy is therefore required to improve the efficacy of vaccination. Objective: To investigate the immunogenicity of third or fourth dose SARS-CoV-2 vaccination strategies in kidney transplant patients. Study design: Prospective, multicentre, open-label randomized clinical trial Study population: Patients with a functioning kidney transplant who did not seroconvert after two or three doses of a mRNA vaccine (either mRNA-1273 (Moderna) or BNT162b2 (Pfizer) or any combination of both) Procedures: Based on their immunosuppressive treatment, patients can participate in one of the following strata: stratum A: patients receiving triple immunosuppressive therapy, consisting of a calcineurin inhibitor, MMF/MPA, and steroids In stratum A, patients will be randomized to one of two equally sized groups. Patients will receive a third or fourth vaccination of the mRNA-1273 vaccine (100 μg, i.m), with either continuation of MMF/MPA (A1) or discontinuation of MMF/MPA during one week before and one week after the third or fourth dose, respectively (A2). stratum B: patients receiving any combination of immunosuppressive drugs. In stratum B, patients will be randomized to one of three equally sized groups. Patients will receive another dose (100 μg, i.m) of the mRNA-1273 vaccine (B1), or two single doses of mRNA-1273 into the left and the right upper arm (2 x 100 μg, i.m; B2), or the Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles, i.m; B3). Main study parameters/endpoints: The primary endpoint is the proportion of patients with an anti-S1 antibody concentration higher than 10 BAU/mL established at 28 days after the third or fourth vaccine administration. Within each stratum different vaccination strategies will be compared. Secondary endpoints include: concentration of anti-S1 antibodies in serum at 28 days after the 3rd or 4th vaccine administration concentration of virus-neutralizing antibodies in serum SARS-CoV-2 specific T cell responses safety in terms of incidence of acute rejection and solicited local and systemic adverse events (AEs) after vaccination. antibody (IgG and IgA) responses in nasal mucosal fluid

2. OBJECTIVES Primary objective: To assess the immunogenicity (expressed as percentage of responders) of various COVID-19 third or fourth vaccination strategies in kidney transplant patients that failed to mount a sufficient antibody response after two or three primary doses of a mRNA vaccine (either mRNA-1273 (Moderna) or BNT162b2 (Pfizer) or any combination of both). Secondary Objectives: To measure the concentration of SARS-CoV-2 spike S1-specific IgG antibodies in serum at 28 days after the 3rd or 4th vaccine administration To measure the presence and titer of neutralizing anti-SARS-CoV-2 antibodies after third or fourth vaccination To evaluate SARS-CoV-2 specific T cell responses To measure anti-S1 antibody (IgG and IgA) responses and neutralizing capacity of these antibodies in nasal mucosal fluid To evaluate vaccine safety in terms of incidence of solicited local and systemic adverse events (AEs) graded according to severity. Exploratory Objectives: To assess the association between baseline clinical and immunological parameters and the immune response to third or fourth vaccinations To correlate RNA-seq data at one week after vaccination to the subsequent antibody and T cell response 3. STUDY DESIGN This is a prospective, multicentre, open-label, randomized study to evaluate the immunogenicity and safety of various third or fourth vaccination strategies in kidney transplant patients without a sufficient antibody response after two or three primary doses of a mRNA vaccine (either mRNA-1273 (Moderna) or BNT162b2 (Pfizer) or any combination of both). The four participating study sites are: Amsterdam UMC, ErasmusMC, Radboudumc and UMCG. Based on their immunosuppressive treatment, patients will participate in one of the following strata: stratum A: patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, stratum B: patients treated with any combination of immunosuppressive drugs. In stratum A, patients will be randomized to one of two third or fourth vaccination strategies: A1: one extra dose of mRNA-1273 (100 μg, i.m) A2: one extra dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the 3rd dose In stratum B, patients will be randomized to one of three third vaccination strategies: B1: 3rd dose of mRNA-1273 (100 μg, i.m) B2: 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms B3: Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.) To assess the immune response after vaccination, blood samples will be collected at baseline (i.e. prior to third dose administration) and at 28 days after the third or fourth dose administration. A complete blood count, kidney function, and liver enzymes will be determined at the same time points. In a subset of patients we will collect a blood sample at 1 week after the third vaccin administration for specific immunological assays. For safety reasons, a blood sample will be collected in stratum A at one and two weeks after discontinuing MMF/MPA. The maximum volume of blood collected for this study is 66 mL per timepoint, and no more than 200 mL for the one year study period, which is well within the safe limits of blood collection for clinical studies. Nasal mucosal lining fluid (MLF) will be collected for assessment of secreted mucosal antibodies at the same time points used to collect blood. MLF will be collected by use of soft synthetic absorptive matrix (SAM) strips, which are gently inserted into one nostril of the participant and placed along the surface of the inferior turbinate. The index finger is then lightly pressed against the side of the nostril to keep the SAM strip in place and to allow MLF absorption for 60 seconds, after which the SAM strip is placed back in the protective plastic tube. The procedure may tickle slightly but is completely painless. To evaluate vaccination related AEs, patients will be asked to collect solicited local and systemic AEs for 7 days after each vaccination using a questionnaire, as vaccination related AEs are mainly expected in the first week after vaccination.

Based on their immunosuppressive treatment, patients will participate in one of the following strata: stratum A: patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, stratum B: patients treated with any combination of immunosuppressive drugs. In stratum A, patients will be randomized to one of two third or fourth vaccination strategies: A1: one extra dose of mRNA-1273 (100 μg, i.m) A2: one extra dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the 3rd dose In stratum B, patients will be randomized to one of three third vaccination strategies: B1: 3rd dose of mRNA-1273 (100 μg, i.m) B2: 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms B3: Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)

Patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m)

patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the extra dose

patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)

patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms

patients treated with any combination of immunosuppressive drugs, receiving a 3rd COVID vaccination with Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)

The percentage of subjects with a serum anti-S1 IgG concentration ≥10 BAU/mL after the third or fourth vaccine administration

Concentrations of SARS-CoV-2 specific antibodies (IgG and IgA) in nasal fluid after third or fourth vaccine administration

Interferon-gamma concentration in whole blood after ex vivo stimulation with SARS-CoV-2 specific peptides Ex vivo production of T cell related cytokines by peripheral blood mononuclear cells (PBMC) in ELISpot assays after third vaccine administration

Percentage of participants reporting local reactions (pain at the injection site, redness and swelling) and systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new of worsened muscle pain, and new or worsened joint pain) after third or fourth vaccine administration

The association between age and development of an antibody and/or T cell response after third or fourth vaccine administration

The association between time after transplantation and development of an antibody and/or T cell response after third or fourth vaccine administration

The association between baseline immunosuppressive medication and development of an antibody and/or T cell response after third or fourth vaccine administration

The association between baseline lymphocytes and development of an antibody and/or T cell response after third or fourth vaccine administration

The association between baseline eGFR and development of an antibody and/or T cell response after third or fourth vaccine administration

Flow cytometry of PBMC for measuring SARS-CoV-2 reactive CD4+ and CD8+ cells after third or fourth vaccine administration

RNA-seq analysis to detect early gene expression that are associated with the development of an antibody and/or T cell response after third or fourth vaccine administration

Inclusion Criteria: Age 18 years or older Received 2 doses of mRNA-1273 (stratum B) according to the recommended vaccination schedule, with the last administration within the last nine months. For stratum A, also patients who received 2 doses of BNT162b2 and/or a third dose with a mRNA vaccine (mRNA-1273 or BNT162b2) within the last three months are eligible. At least 6 months after kidney transplantation Negative seroresponse 14 to 56 days after vaccination, measured by a validated anti-spike IgG assay of which the definition is dependent on the assay that is used. Eligible for COVID-19 vaccination as described by the instructions of the manufacturers of the vaccine (Moderna and Janssen) Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) Willing to adhere to the protocol and be available during the study period Additional inclusion criteria to be eligible for stratum A: Maintenance immunosuppressive therapy consisting of a calcineurin inhibitor (tacrolimus or cyclosporine), MMF/MPA, and prednisone In case of tacrolimus treatment: last tacrolimus pre-dose level while on current dosage above 4 μg/l In case of cyclosporine treatment: last cyclosporine pre-dose level while on current dosage above 75 μg/l Prednisone dose at least 5 mg/day First or second transplantation Calculated level of panel reactive antibodies prior to last transplantation below 85% No signs of acute rejection during the preceding year Exclusion Criteria: Multi-organ transplant recipient History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s). Previous or active COVID-19 disease Active malignancy, except non-melanoma skin cancer Inherited immune deficiency Infection with Human Immunodeficiency Virus (HIV) Administration of T cell, B cell, or plasma cell depleting antibodies during the last 6 months Any vaccination within a week before enrolment Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. Additional exclusion criteria for stratum B: History of recurrent venous thrombosis or venous thrombosis <2 years before baseline Immune-mediated diseases associated with thrombocytopenia such as ITP and aHUS

Kho MML, Messchendorp AL, Frolke SC, Imhof C, Koomen VJ, Malahe SRK, Vart P, Geers D, de Vries RD, GeurtsvanKessel CH, Baan CC, van der Molen RG, Diavatopoulos DA, Remmerswaal EBM, van Baarle D, van Binnendijk R, den Hartog G, de Vries APJ, Gansevoort RT, Bemelman FJ, Reinders MEJ, Sanders JF, Hilbrands LB; RECOVAC collaborators. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. Lancet Infect Dis. 2023 Mar;23(3):307-319. doi: 10.1016/S1473-3099(22)00650-8. Epub 2022 Oct 27.